Company profile: Emperra
1.1 - Company Overview
Company description
- Provider of GSM- and web-based telemedical solutions for diabetes management, enabling tracking, monitoring and transmission of insulin doses, blood glucose and carbohydrate data. Offers the ESYSTA system with automatic capture of insulin units and blood glucose, plus the ESYSTA Portal and App for authorized healthcare professionals to adjust treatment. Runs the ESYSTA S-T-A-R-T field trial with a smart insulin pen and telemonitoring in statutory health insurance.
Products and services
- ESYSTA Portal and App: Delivers a web-based database of insulin doses and blood glucose data for treatment adjustments by authorized healthcare professionals
- ESYSTA: Engineers a GSM-enabled telemedicine system integrating automatic capture of insulin units and blood glucose, and tracking plus transmission of diagnostic/therapeutic data
- ESYSTA S-T-A-R-T Project: Executes a field-trial initiative in a statutory health insurance setting aiming at metabolic optimisation for diabetics by employing a smart insulin pen and telemonitoring
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Emperra
Animas
HQ: United States
Website
- Description: Provider of external insulin pumps for people with diabetes, designing, developing, manufacturing, and selling these devices. Believed to be the second-largest supplier in the U.S. by new pump placements. Introduced the R1000 in July 2000 and expects to begin shipping its third-generation pump.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Animas company profile →
Medicore
HQ: United States
Website
- Description: Provider of blood collection and diabetic care products, manufacturing and distributing to hospitals and medical companies. Holds multiple contracts with hospital group purchasing organizations, with product line available through nearly all major medical device distributors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medicore company profile →
Orpyx
HQ: Canada
Website
- Description: Provider of sensor-based technologies and self-monitoring devices for medical and athletic applications, including the Orpyx SI Sensory Insole System to monitor plantar pressure, adherence, step count, and temperature for peripheral neuropathy patients to reduce diabetic foot ulcer risk. Offers remote patient monitoring with data science-based triage by credentialed providers and nurses and a Diabetes Healthspan Extension for personalized remote care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orpyx company profile →
Dexcom
HQ: United States
Website
- Description: Provider of continuous glucose monitoring systems and data services for diabetes management, developing, manufacturing and distributing Dexcom G7 (real-time readings and alerts, compatible with Apple Watch), Dexcom G6 (for users 2+), and the OTC Stelo Glucose Biosensor System for adults not on insulin, plus Dexcom Clarity for glucose data analysis and Dexcom Follow/Share for remote data sharing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dexcom company profile →
Adocia
HQ: France
Website
- Description: Provider of biotechnology therapies specializing in tissue regeneration and diabetes treatments, developing medicines with already-approved therapeutic proteins. Offerings include BioChaperone Lispro ultra-rapid insulin, BioChaperone Combo glargine+lispro, AdoShell Islets hydrogel implant, M1Pram and BioChaperone LisPram co-formulations, and AdOral Sema oral semaglutide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adocia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Emperra
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Emperra
2.2 - Growth funds investing in similar companies to Emperra
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Emperra
4.2 - Public trading comparable groups for Emperra
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →